Literature DB >> 12574805

Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.

Judith Leurs1, Britt-Marie Wissing, Viveca Nerme, Katinka Schatteman, Petter Björquist, Dirk Hendriks.   

Abstract

Carboxypeptidase U (CPU,TAFIa) recently gained interest as a significant player in dampening the fibrinolytic rate. The aim of this study was to investigate the time course of the generation of CPU activity during coagulation and fibrinolysis using an in vitro clot lysis model in human plasma. A first peak of CPU activity appeared after initiation of the coagulation phase and a second rise in CPU activity was observed during the fibrinolysis. The decrease in the proCPU plasma concentration followed the same trend as the appearance of the CPU activity. The direct thrombin inhibitor inogatran eliminated the CPU generation during coagulation but not during fibrinolysis. Addition of the plasmin inhibitor aprotinin during fibrinolysis resulted in a decrease in CPU activation during the lysis phase. These results demonstrate that proCPU was activated during coagulation by thrombin and during fibrinolysis by plasmin. Addition of a CPU inhibitor before initiation of clotting decreased the clot lysis time as expected. However, addition in the time period between the two peaks of CPU activity had no apparent effect on the clot lysis time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574805

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

Authors:  Yuko Suzuki; Hideto Sano; Liina Mochizuki; Naoki Honkura; Tetsumei Urano
Journal:  Blood Adv       Date:  2020-11-10

Review 2.  Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

Authors:  Tatjana Elène Vogelvang; Marius Jan van der Mooren; Velja Mijatovic; Peter Kenemans
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

Review 4.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

5.  Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.

Authors:  Marianne Månsson; Inge Kalies; Göran Bergström; Caroline Schmidt; Anne Legnehed; Lillemor Mattsson Hultén; Lena Amrot-Fors; David Gustafsson; Wolfgang Knecht
Journal:  Sci Rep       Date:  2014-06-17       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.